Mathew A Kozman1,2, Oliver M Fisher1,2,3, Bree-Anne J Rebolledo1, Roneil Parikh1, Sarah J Valle1, Arief Arrowaili4, Nayef Alzahrani1,2,4, Winston Liauw2,5, David L Morris1,2. 1. Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW, Australia. 2. St George Hospital Clinical School, University of New South Wales, Sydney, NSW, Australia. 3. School of Medicine, University of Notre Dame, Sydney, NSW, Australia. 4. College of Medicine, Al-Imam Mohammad Ibn Saud Ismalic University, Riyadh, Saudi Arabia. 5. Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.
Abstract
BACKGROUND AND OBJECTIVES: Serum tumor markers are prognostic in patients with colorectal cancer peritoneal carcinomatosis (CRPC) undergoing cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC). Assessment of the ratio of tumor marker to volume, as depicted by peritoneal carcinomatosis index (PCI), and how this may affect overall (OS) and recurrence free survival (RFS) has not been reported. METHODS: Survival effect of this ratio was analyzed in patients with CRPC managed from 1996 to 2016 with CRS and IPC. RESULTS: Of 260 patients included, those with low CEA/PCI ratio (<2.3) had longer median OS (56 vs 24 months, P = 0.001) and RFS (13 vs 9 months, P = 0.02). The prognostic impact of CEA/PCI ratio was most pronounced in patients with PCI ≤ 10 (OS of 72 vs 30 months, P < 0.001; RFS of 21 vs 10 months, P = 0.002). In multivariable analysis, elevated CEA/PCI ratio was independently associated with poorer OS (adjusted HR 1.85, 95%CI 1.11-3.10, P = 0.02) and RFS (adjusted HR 1.58, 95%CI 1.04-2.41, P = 0.03). CONCLUSION: CEA/PCI ratio is an independent prognostic factor for OS and RFS in CRPC. This novel approach allows both tumor activity and volume to be accounted for in one index, thus potentially providing a more accurate indication of tumor biological behavior.
BACKGROUND AND OBJECTIVES: Serum tumor markers are prognostic in patients with colorectal cancer peritoneal carcinomatosis (CRPC) undergoing cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC). Assessment of the ratio of tumor marker to volume, as depicted by peritoneal carcinomatosis index (PCI), and how this may affect overall (OS) and recurrence free survival (RFS) has not been reported. METHODS: Survival effect of this ratio was analyzed in patients with CRPC managed from 1996 to 2016 with CRS and IPC. RESULTS: Of 260 patients included, those with low CEA/PCI ratio (<2.3) had longer median OS (56 vs 24 months, P = 0.001) and RFS (13 vs 9 months, P = 0.02). The prognostic impact of CEA/PCI ratio was most pronounced in patients with PCI ≤ 10 (OS of 72 vs 30 months, P < 0.001; RFS of 21 vs 10 months, P = 0.002). In multivariable analysis, elevated CEA/PCI ratio was independently associated with poorer OS (adjusted HR 1.85, 95%CI 1.11-3.10, P = 0.02) and RFS (adjusted HR 1.58, 95%CI 1.04-2.41, P = 0.03). CONCLUSION:CEA/PCI ratio is an independent prognostic factor for OS and RFS in CRPC. This novel approach allows both tumor activity and volume to be accounted for in one index, thus potentially providing a more accurate indication of tumor biological behavior.
Authors: Can He; Niresh Thapa; Yang Wang; Ziye Song; Jing Yang; Mengfei Xu; Na Zuo; Hongbing Cai Journal: Cancer Manag Res Date: 2020-03-25 Impact factor: 3.989
Authors: Jian Lv; Yuan Yuan Liu; Yi Tao Jia; Jing Li He; Guang Yao Dai; Peng Guo; Zhao Long Zhao; Yan Ni Zhang; Zhong Xin Li Journal: World J Surg Oncol Date: 2021-12-02 Impact factor: 2.754
Authors: Michael P Flood; Joseph C H Kong; Kasmira Wilson; Helen Mohan; Peadar S Waters; Jacob J McCormick; Satish K Warrier; Jeanne Tie; Robert Ramsay; Michael Michael; Alexander G Heriot Journal: Ann Surg Oncol Date: 2022-04-09 Impact factor: 4.339